Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when XOMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsXOMA Royalty amends Ligand merger agreement to add holding company reorganization step
Filed May 18, 2026 · Period ending May 16, 2026 · ~1 min read
Key Changes
-
high
XOMA amended its merger agreement with Ligand Pharmaceuticals to add a newly formed subsidiary (HoldCo) as a party, enabling a holding company reorganization under Nevada law before the merger closes.
Item 1.01 verify on EDGAR → -
medium
The holding company reorganization is a new condition that must be completed before the Ligand merger can close, adding a structural step to the previously announced transaction.
Item 1.01 verify on EDGAR → -
medium
HoldCo is a wholly-owned subsidiary formed solely for this reorganization purpose and will become the surviving entity after Ligand's merger subsidiary merges into it.
Item 1.01 verify on EDGAR →
Summary
XOMA Royalty has amended its previously announced merger agreement with Ligand Pharmaceuticals to insert an additional structural step before the deal closes. The company created a new wholly-owned subsidiary called XOMA Royalty Holdings Corporation (HoldCo) and amended the merger agreement to make HoldCo a party to the transaction. This enables a holding company reorganization under Nevada law that must now be completed before the Ligand merger can finalize.
For XOMA shareholders, this amendment adds complexity to the deal structure but appears procedural rather than substantive—the filing doesn't indicate changes to pricing, timing, or other material deal terms. However, the addition of a new closing condition (the holding company reorganization) introduces a step that could potentially delay or complicate the transaction. Investors should watch for the proxy statement or additional disclosures that explain why this reorganization was deemed necessary and whether it affects shareholder approval requirements or the expected closing timeline for the Ligand merger.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 16, 2026, XOMA Royalty, Parent and the Merger Sub entered into Amendment No. 1 to the Agreement and Plan of Merger (“Amendment No. 1”) which, among other things, adds HoldCo as a party to the Merger Agreement.
XOMA Royalty executed Amendment No. 1 to its previously announced merger agreement with Ligand Pharmaceuticals. The amendment adds XOMA Royalty Holdings Corporation (HoldCo), a newly formed wholly-owned subsidiary, as a party to the merger agreement. HoldCo was created specifically to facilitate a holding company reorganization under Nevada law before the merger with Ligand's subsidiary is completed.
Added in current filing · verify on EDGAR →
HoldCo is a wholly-owned subsidiary of XOMA Royalty and was formed for the sole purpose of effecting a holding company reorganization (the “Holding Company Reorganization”) pursuant to Nevada Revised Statutes, as amended (“NRS”), 92A (or such other applicable provisions of the NRS).
The company disclosed that HoldCo is a newly formed wholly-owned subsidiary created solely to execute a holding company reorganization under Nevada law. This reorganization is a condition that must be completed before the merger with Ligand Pharmaceuticals can close. The structure involves HoldCo becoming the surviving entity after Ligand's merger subsidiary merges into it.
Event · Item 9.01 — Financial Statements and Exhibits
XOMA Royalty filed Amendment No. 1 to its merger agreement with Ligand Pharmaceuticals, modifying terms of the previously announced transaction.
Added in current filing · verify on EDGAR →
Amendment No. 1 to the Agreement and Plan of Merger, dated as of May 16, 2026, by and among XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc.
XOMA Royalty has executed an amendment to its merger agreement with Ligand Pharmaceuticals. The amendment modifies the original merger agreement between the parties, though the specific changes are not detailed in this 8-K filing itself. Investors should review the attached exhibit for material terms that may affect deal structure, timing, pricing, or conditions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify